https://www.europesays.com/britain/136107/ SMMT Stock Gets Another Catalyst: Summit, AstraZeneca, Daiichi Sankyo Expand Cancer Drug Push #Akeso #AstraZeneca #AZN #BiotechStocks #CancerImmunotherapy #DaiichiSankyo #Datroway #FDADecisionOnSummit #HARMONiTrial #ivonescimab #NonSmallCellLungCancerTreatments #SMMTStock #SummitTherapeutics #TripleNegativeBreastCancer
#daiichisankyo — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #daiichisankyo, aggregated by home.social.
-
https://www.csseo.org/1330031/ Katia Massaroni nominata Executive Medical Director di Amgen per Italia e Grecia #AlessandraBrescianini #AmgenItalia #DaiichiSankyo #DirezioneMedica #ExecutiveMedicalDirector #ExecutiveMedicalDirectorThoracicOncologyandBiosimilars #GlobalMedicalOncologydiAmgen #Grecia #ItaliaeGrecia #KatiaMassaroni #Novartis
-
GSK’s ADC lays down marker for lung cancer scrap with Merck
GSK’s risvutatug rezetecan (ris-rez) has achieved a median overall survival (OS) of 18.5 months in a phase 3…
#EuropeSays #Britain #Europe #EU #GSK #Amgen #antibody-drugconjugates #biotech #clinicaldata #DaiichiSankyo #FierceBiotechHomepage #HansohPharma #Merck&Co. #smallcelllungcancer #solidtumor
https://www.europesays.com/britain/130843/ -
https://www.europesays.com/britain/130843/ GSK’s ADC lays down marker for lung cancer scrap with Merck #Amgen #AntibodyDrugConjugates #biotech #ClinicalData #DaiichiSankyo #FierceBiotechHomepage #GSK #HansohPharma #Merck&Co #SmallCellLungCancer #SolidTumor
-
IHH Healthcare Unit Appeals Tokyo Court Ruling That Blocked $1.1 Billion Damages Claim — BigGo Finance
IHH Healthcare’s subsidiary Northern TK Venture has appealed a Tokyo court’s dismissal of its damages claim against Daiichi…
#EuropeSays #Japan #JP #Tokyo #DaiichiSankyo #IHHHealthcare #FortisHealthcare #NorthernTKVenture #Tokyocourt
https://www.europesays.com/japan/96455/ -
https://www.europesays.com/es/779835/ ¿Qué pasa con un medicamento cuando llega a la consulta? El reto de medir su impacto real #A1 #bayer #BeOneMedicines #Business #Communis2026 #DaiichiSankyo #Economía #Economy #ES #España #Laboratorios #lundbeck #MesaDeExpertos #Spain
-
AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo’s Enhertu has been cleared for use by England’s National Health Service (NHS)…
#EuropeSays #Britain #Europe #EU #AstraZeneca #AstraZenecaPLC #breAstcancer #DaiichiSankyo #England #incrementalrevenue #metastaticbreastcancer
https://www.europesays.com/britain/128910/ -
https://www.europesays.com/britain/128910/ AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England #AstraZeneca #AstraZenecaPLC #BreAstCancer #DaiichiSankyo #England #IncrementalRevenue #MetastaticBreastCancer
-
AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success
AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced…
#EuropeSays #Britain #Europe #EU #AstraZeneca #chronicconditions #DaiichiSankyo #Lungcancer #obstructivepulmonarydisease #respiratorydisease
https://www.europesays.com/britain/126565/ -
https://www.europesays.com/britain/126565/ AstraZeneca (LSE:AZN) Reported First HER2 Directed Lung Cancer Phase III Success #AstraZeneca #ChronicConditions #DaiichiSankyo #LungCancer #ObstructivePulmonaryDisease #RespiratoryDisease
-
https://www.europesays.com/britain/126122/ AstraZeneca-Daiichi get nod for NHS to use breast cancer drug in England #AstraZeneca #BreastCancerTreatment #CancerDrugReimbursement #chemotherapy #CostEffectivenessNHSDrugs #DaiichiSankyo #HER2LowMetastaticBreastCancer #NationalHealthService #NationalInstituteForHealthAndCareExcellence #NHSEngland #NiceApproval #OncologyDrugApproval #UKHealthCare
-
https://www.europesays.com/britain/126101/ AstraZeneca-Daiichi get nod for NHS to use breast cancer drug in England #AstraZeneca #BreastCancerTreatment #CancerDrugReimbursement #chemotherapy #CostEffectivenessNHSDrugs #DaiichiSankyo #HER2LowMetastaticBreastCancer #NationalHealthService #NationalInstituteForHealthAndCareExcellence #NHSEngland #NiceApproval #OncologyDrugApproval #UKHealthCare
-
AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England
LONDON, Sept 17 (Reuters) – AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has…
#EuropeSays #Britain #Europe #EU #AstraZeneca #breAstcancer #breastcancertreatment #DaiichiSankyo #Drugprices #England #metastaticbreastcancer #theNationalInstituteforHealthandCareExcellence #UK
https://www.europesays.com/britain/126014/ -
https://www.europesays.com/britain/126014/ AstraZeneca-Daiichi breast cancer drug cleared for NHS use in England #AstraZeneca #BreAstCancer #BreastCancerTreatment #DaiichiSankyo #DrugPrices #England #MetastaticBreastCancer #TheNationalInstituteForHealthAndCareExcellence #UK
-
AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer
Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a…
#EuropeSays #Britain #Europe #EU #AstraZeneca #DaiichiSankyo’sENHERTUCutsDiseaseProgressionRiskby37%inHER2-MutantLungCancer
https://www.europesays.com/britain/125176/ -
https://www.europesays.com/britain/125176/ AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer #AstraZeneca #DaiichiSankyo’sENHERTUCutsDiseaseProgressionRiskBy37%InHER2MutantLungCancer
-
https://www.europesays.com/britain/124949/ Enhertu EU Milestone And Legal Win Might Change The Case For Investing In Daiichi Sankyo (TSE:4568) #AstraZeneca #DaiichiSankyo #Enhertu #MilestonePayment #RevenueGrowth
-
Enhertu EU Milestone And Legal Win Might Change The Case For Investing In Daiichi Sankyo (TSE:4568)
Daiichi Sankyo and AstraZeneca’s Enhertu, in combination with pertuzumab, was approved in the European Union in September 2026…
#EuropeSays #Britain #Europe #EU #AstraZeneca #DaiichiSankyo #Enhertu #milestonepayment #Revenuegrowth
https://www.europesays.com/britain/124949/ -
Tokyo court dismisses IHH unit’s claims against Daishi Sankyo
KUALA LUMPUR: The Tokyo District Court has dismissed all claims brought by IHH Healthcare Bhd’s indirect wholly-owned subsidiary…
#EuropeSays #Japan #JP #Tokyo #DaiichiSankyo #IHHHealthcare #CorporateNews #FortisHealthcare #NorthernTKVenturePteLtd #TokyoDistrictCourt
https://www.europesays.com/japan/89581/ -
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab …
#Europe #EU #astrazeneca #DaiichiSankyo #Enhertu #EuropeanUnion #Inc."This #OncologyBusiness #OncologyHematologyBusinessUnit #TheNewEnglandJournalofMedicine #THP
https://www.europesays.com/europe/127621/ -
Fierce Pharma Asia—China’s IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe’s dermatology deal
China’s investigator-initiated trials, once praised for their speediness, have been drawn into scrutiny for a lack of transparency.…
#EuropeSays #Britain #Europe #EU #AstraZeneca #Asia #biosimilar #DaiichiSankyo #FiercePharmaAsia #FiercePharmaHomepage #genetherapy #MitsubishiTanabePharma #Pharma #phase3 #ShanghaiHenliusBiotechnology
https://www.europesays.com/britain/108180/ -
https://www.europesays.com/britain/108180/ Fierce Pharma Asia—China’s IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe’s dermatology deal #Asia #AstraZeneca #biosimilar #DaiichiSankyo #FiercePharmaAsia #FiercePharmaHomepage #GeneTherapy #MitsubishiTanabePharma #Pharma #Phase3 #ShanghaiHenliusBiotechnology
-
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda — BigGo Finance
AstraZeneca has terminated a late-stage clinical trial for its experimental bispecific antibody volrustomig in metastatic non-small cell lung…
#EuropeSays #Britain #Europe #EU #AstraZeneca #Camizestrant #DaiichiSankyo #Enhertu #IonisPharmaceuticals #Keytruda #MSD) #Orpathys #SusanGalbraith #Tagrisso #Ultomiris #volrustomig #Wainua
https://www.europesays.com/britain/105544/ -
https://www.europesays.com/britain/105544/ AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda — BigGo Finance #AstraZeneca #Camizestrant #DaiichiSankyo #Enhertu #IonisPharmaceuticals #Keytruda #MSD) #Orpathys #SusanGalbraith #Tagrisso #Ultomiris #volrustomig #Wainua
-
AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure
AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although…
#EuropeSays #Britain #Europe #EU #AstraZeneca #antibody-drugconjugates #clinicaldata #DaiichiSankyo #EGFR-mutatedlungcancer #Enhertu #FiercePharmaHomepage #HER2 #Hutchmed #METinhibitor #non-smallcelllungcancer #Pharma #savolitinib #Tagrisso
https://www.europesays.com/britain/105261/ -
https://www.europesays.com/britain/105261/ AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure #AntibodyDrugConjugates #AstraZeneca #ClinicalData #DaiichiSankyo #EGFRMutatedLungCancer #Enhertu #FiercePharmaHomepage #HER2 #Hutchmed #METInhibitor #NonSmallCellLungCancer #Pharma #savolitinib #Tagrisso
-
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives…
#France #FR #Europe #EU #Sanofi #Astellas #BoehringerIngelheim #BristolMyersSquibb #DaiichiSankyo #Dupixent #EliLilly #FiercePharmaHomepage #NovoNordisk #pharma #QuarterlySales #RegeneronPharmaceuticals #Takeda
https://www.europesays.com/france/64664/ -
Daiichi Sankyo wins EU approval for Datroway in TNBC
KEY POINTSDaiichi Sankyo wins EU approval for Datroway in first-line unresectable or metastatic triple-negative breast cancer outside PD-1/PD-L1…
#Europe #EU #astrazeneca #DaiichiSankyo #datopotamabderuxtecan #Datroway #EuropeanUnion #oncology #triplenegativebreastcancer #TROPION-Breast02
https://www.europesays.com/europe/106901/ -
https://www.europesays.com/britain/94511/ Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy #AdultPatients #AstraZeneca #BreAstCancer #chemotherapy #DaiichiSankyo #IncludedPatients #MetastaticDisease #ProgressionFreeSurvival #TNBC
-
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s…
#Europe #EU #adultpatients #astrazeneca #breastcancer #Chemotherapy #DaiichiSankyo #EuropeanUnion #includedpatients #metastaticdisease #progression-freesurvival #TNBC
https://www.europesays.com/europe/106410/ -
To reduce its reliance on Enhertu ahead of the cancer treatment's patent expiry, Daiichi Sankyo is betting on a new wave of antibody-drug conjugates to expand its oncology business. https://www.japantimes.co.jp/business/2026/05/12/companies/daiichi-sankyo-new-cancer-drugs/?utm_medium=Social&utm_source=mastodon #business #companies #daiichisankyo #health #pharmaceuticals #medicine #patents
-
A Japanese panel of experts gave the green light for the health minister to approve the production and sale of Daiichi Sankyo's vaccine for measles, mumps and rubella. https://www.japantimes.co.jp/news/2026/03/03/japan/science-health/mmr-vaccine-ok-expert-panel/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #daiichisankyo #vaccinations #health #covid19 #medicine
-
Daiichi Sankyo said it would start over-the-counter sales of an emergency contraceptive pill on Feb. 2, marking the first time that such a pill will be sold without a prescription in Japan. https://www.japantimes.co.jp/news/2025/12/18/japan/science-health/japan-otc-emergency-contraception/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #pharmaceutical #health #pregnancy #birthcontrol #daiichisankyo
-
AstraZeneca och Daiichi Sankyo presenterar de starkaste överlevnadsdata som hittills uppnåtts för patienter med metastaserande trippelnegativ bröstcancer utan möjlighet till immunterapi. https://borsposten.se/astrazeneca-visar-genombrottsresultat-for-datroway-vid-svar-brostcancer/ #aktier #AstraZeneca #DaiichiSankyo
-
AstraZeneca and Daiichi Sankyo’s drug Datroway has significantly improved survival and delayed the progression of breast cancer in patients with a particularly hard to treat form of the disease, AstraZeneca has said. https://www.japantimes.co.jp/business/2025/10/07/companies/astrazeneca-breast-cancer/?utm_medium=Social&utm_source=mastodon #business #companies #astrazeneca #daiichisankyo #health #cancer #medicine #pharmaceuticals
-
Japan’s Daiichi Sankyo establishes third research institute in US
Japan’s Daiichi Sankyo establishes third research institute in US October 3, 2025 | Friday | News Advancing the vision of Daiichi Sankyo to foster the development of next-generation medicines image credit- shutterstock Japanese pharmaceutical fi…
#Japan #JP #JapanNews #DaiichiSankyo #europe #JapanTopics #news #ResearchInstitutes #us
https://www.alojapan.com/1383602/japans-daiichi-sankyo-establishes-third-research-institute-in-us/ -
https://www.alojapan.com/1383602/japans-daiichi-sankyo-establishes-third-research-institute-in-us/ Japan’s Daiichi Sankyo establishes third research institute in US #DaiichiSankyo #europe #Japan #JapanNews #JapanTopics #news #ResearchInstitutes #us Japan’s Daiichi Sankyo establishes third research institute in US October 3, 2025 | Friday | News Advancing the vision of Daiichi Sankyo to foster the development of next-generation medicines image credit- shutterstock Japanese pharmaceutical firm Daiichi Sankyo has established Daiichi San
-
-
AstraZeneca and Daiichi Sankyo’s Datroway breast cancer treatment, which the companies expect will eventually become a blockbuster, was recommended for approval in the European Union. https://www.japantimes.co.jp/business/2025/01/31/astrazeneca-daiichi-eu-approval/?utm_medium=Social&utm_source=mastodon #business #daiichisankyo #astrazeneca #cancer #medicine #pharmaceuticals #eu
-
Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster. https://www.japantimes.co.jp/business/2025/01/20/companies/daiichi-sankyo-breast-cancer-treatment/?utm_medium=Social&utm_source=mastodon #business #companies #daiichisankyo #pharmaceuticals #breastcancer #us #astrazeneca
-
AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast cancer treatment, a milestone in the companies’ efforts to turn the medicine into a widely used blockbuster. https://www.japantimes.co.jp/business/2025/01/18/cancer-drug-astrazeneca-daiichi/?utm_medium=Social&utm_source=mastodon #business #daiichisankyo #astrazeneca #medicine #cancer #pharmaceuticals
-
Tokyo District Court on Wednesday sentenced a former employee of drugmaker Daiichi Sankyo to 16 years in prison for the murder of his wife by methanol poisoning in 2022. https://www.japantimes.co.jp/news/2024/10/31/japan/crime-legal/methanol-murder-16-years-prison/ #japan #crimelegal #drugs #japanesecourts #daiichisankyo
-
Prosecutors have called for an 18-year prison sentence for Keisuke Yoshida, a 42-year-old former employee of pharmaceutical giant Daiichi Sankyo, who is on trial for the methanol poisoning death of his wife. https://www.japantimes.co.jp/news/2024/10/11/japan/crime-legal/methanol-poisoning-trial/ #japan #crimelegal #japanesecourts #tokyo #daiichisankyo
-
Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the United States. https://www.japantimes.co.jp/business/2024/10/11/companies/daiichi-sankyo-cancer-drug/ #business #companies #daiichisankyo #cancer #drugs #astrazeneca
-
Cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this time it might not need a partner to get it over the line. https://www.japantimes.co.jp/news/2024/09/17/japan/science-health/daiichi-sankyo-cancer-drugs/ #japan #sciencehealth #daiichisankyo #pharmaceutical #medicine #cancer #drugs
-
A former employee of pharmaceutical company Daiichi Sankyo who is accused of poisoning his wife to death with methanol in 2022 denied the charge on Monday. https://www.japantimes.co.jp/news/2024/09/02/japan/crime-legal/court-methanol-poisoning/ #japan #crimelegal #japanesecourt #tokyo #otaward #daiichisankyo
-
The COVID-19 pandemic highlighted many weaknesses in Japan’s health care system. It's now time to fix them with a global perspective, says health minister Keizo Takemi. https://www.japantimes.co.jp/news/2024/08/14/japan/science-health/health-minister-keizo-takemi-interview/ #japan #sciencehealth #keizotakemi #dementia #aging #pandemic #covid19 #medicine #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines
-
Health Minister Keizo Takemi sat down with the Japan Times to talk about his vision of digitalizing Japan’s health care system, as well as sharing the country’s medical know-how with other Asian nations. https://www.japantimes.co.jp/news/2024/08/14/japan/science-health/health-minister-keizo-takemi-interview-124346/ #japan #sciencehealth #keizotakemi #dementia #aging #pandemic #covid19 #medicine #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines
-
Repertoire pivot pays dividends with Bristol Myers deal—AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial —Ono swoops on Deciphera in $2.4 billion takeover--http://bit.ly/w28kSd #bristolmyerssquibb #astrazeneca #daiichisankyo #breastcancer #clinicaltrials #mergersandacquisitions #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
#Bayern #Oberbayern #LandkreisPfaffenhofen
#PfaffenhofenanderIlm #Krebstherapien #Produkt
#DaiichiSankyo #Investitionen #EineMilliardeEuro
AUFBAU VON PRODUKTION NEUARTIGER KREBSTHERAPIEN -
Daiichi Sankyo investiert eine Milliarde Euro in Pfaffenhofen:
-
Daiichi invests 1 bln eur near Munich to make precision cancer drugs —FDA to review Sarepta's Duchenne gene therapy for traditional approval —Denali-Sanofi's ALS drug fails to meet mid-stage trial goal--http://bit.ly/w28kSd #daiichisankyo #germany #cancer #dmd #sarepta #als #sanofi #clinicaltrials #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Japan’s health ministry approved the first domestically developed COVID-19 vaccine that works against the currently circulating XBB.1.5 sublineage of the omicron variant. https://www.japantimes.co.jp/news/2023/11/28/japan/science-health/daiichi-sankyo-covid-vaccine/?utm_content=bufferc45df&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines #medicine #covid19
-
U.S. drugmaker Merck will pay Daiichi Sankyo $5.5 billion (about ¥824.7 billion) to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm. https://www.japantimes.co.jp/business/2023/10/20/daiichi-sankyo-merck-cancer-deal/?utm_content=bufferfef3c&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #business #daiichisankyo #merck #health #medicine #cancer
-
FDA staff hold ‘major concerns’ with Brainstorm ALS therapy, documents show -- Daiichi Sankyo reports positive results from trial of breast cancer therapy -- AbbVie ends I-Mab partnership for CD47 antibody compounds -- See more on our front page news http://bit.ly/w28kSd #fda #als #brainstormcelltherapeutics #daiichisankyo #clinicaltrials #breastcancer #antibodies #abbvie #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Biogen, Sage's postpartum depression approval overshadowed by larger rejection -- 10 clinical trials to watch in the second half of 2023 -- Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments-- See more on our front page news http://bit.ly/w28kSd #biogen #sagetherapeutics #fda #postpartumrejection #clinicaltrials #daiichisankyo #oncology #cancer #antibodydrugconjugate #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
A Japanese health ministry panel has endorsed a COVID-19 vaccine developed by pharmaceutical company Daiichi Sankyo, a first for a domestically developed shot. https://www.japantimes.co.jp/news/2023/08/01/japan/science-health/japan-panel-endorses-first-domestically-developed-covid-vaccine/?utm_content=buffer0d11e&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines #medicine #shionogi #covid19
-
Three biotech stocks riding the AI wave like none other—FDA okays Daiichi Sankyo’s Vanflyta for first-line AML -- Sleepless nights for 500 Idorsia staff as biotech halves cash burn to outlast weak insomnia drug sales -- See more on our front page news http://bit.ly/w28kSd #ai #artificialintelligence #fda #daiichisankyo #aml #layoffs #insomnia #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Daiichi Sankyo is expanding its sales and development staff overseas, aiming to boost production capacity so that it can handle its cancer drugs business entirely on its own. https://www.japantimes.co.jp/news/2023/06/07/business/corporate-business/daiichi-sankyo-interview/?utm_content=buffer3a51c&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #corporate #cancer #astrazeneca #daiichisankyo #medicine #enhertu